Technical Title: Hypo-fractionated Stereotactic Body Radiotherapy for High-Risk Localized Prostate Cancer
UCLA Department of Radiation Oncology is conducting a study that researches the effect of hypo-fractionated radiotherapy, also known as stereotactic body radiotherapy (SBRT), for those diagnosed with high-risk prostate cancer. This type of radiotherapy divides the total prescribed dose of radiation into fewer but larger doses as compared to conventional external beam radiotherapy.
We hope to see that delivering higher, but more accurately targeted doses of radiation will be more effective and better tolerated than concurrent standard methods when used in treatment of patients.
Study visits will be approximately every 3 months for the first 2 years, and then approximately every 6 months for up to 5 years. At each visit, a Quality of Life questionnaire much be completed, and PSA levels are monitored. Patients are expected to participate in follow-up for a minimum of 3 years and will be encouraged to continue follow-up for up to 5 years.
After the first follow-up visit has been performed, patients will have the option to obtain their blood work at an outside facility for convenience (i.e. subject has moved out of state/country; has difficulty returning to the clinic for follow-up, etc.) and completed QOL questionnaires can be returned via mail or fax.
For More Detailed Information Contact:
UCLA Department of Radiation Oncology (310) 825-6577